Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.49 (
phosphoenolpyruvate carboxykinase
)
4,654
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Incubation of partially purified yeast
phosphoenolpyruvate carboxykinase
(
ATP:oxaloacetate carboxy-lyase
(transphosphorylating),
EC 4.1.1.49
) with 5% mercaptoethanol and 0.01% sodium dodecyl sulfate at 37 degrees C results in degradation of the enzyme. The degradation can be partially prevented by addition of proteinase B inhibitor 2 or phenylmethylsulfonyl fluoride, an inhibitor of proteinase B and carboxypeptidase Y. The degradation can be completely inhibited by addition of proteinase B inhibitor 2 together with pepstatin, and inhibitor of
proteinase A
. Thus it appears that proteolytic activities are firmly attached to
phosphoenolpyruvate carboxykinase
and are identical with the yeast proteinases A and B. The latter conclusion was supported by experiments using the pure yeast proteinases.
...
PMID:Characterization of the proteolytic activity firmly attached to yeast phoshoenolpyruvate carboxykinase. 705 35
